Lydia A. Herrera

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Caspofungin is the first member of the echinocandin class of antifungals to receive an indication for the use in infants, children, and adolescents from the United States Food and Drug Administration. Daily doses of 50 mg/m(2) result in pharmacokinetic parameters that are similar to those observed in adults. Although fewer data are available, the response(More)
  • 1